Frontotemporal Dementia (FTD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Frontotemporal Dementia (FTD) Market Outlook

Thelansis’s “Frontotemporal Dementia (FTD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Frontotemporal Dementia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Frontotemporal Dementia (FTD) Overview

Frontotemporal dementia (FTD) is a range of neurodegenerative disorders characterized by diverse clinical manifestations and two main underlying neuropathological profiles. Within FTD, there are typically three distinct clinical syndromes: behavioral variant frontotemporal dementia (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent variant primary progressive aphasia (nfvPPA). Furthermore, FTD often exhibits clinical and neuropathological overlaps with three other neurodegenerative conditions: corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS). These syndromes can be associated with different underlying neuropathological diagnoses collectively termed frontotemporal lobar degeneration (FTLD). The most prevalent forms of FTD are as follows:

1. Frontal variant: This type primarily impacts behavior and personality.
2. Primary progressive aphasia: This category involves communication difficulties and has two subtypes:

• Progressive nonfluent aphasia, which impairs speech abilities.
• Semantic dementia, which hampers language comprehension and usage.

Up to 50% of FTD cases with autosomal-dominant inheritance have a family history of FTD. Clinical diagnoses include behavioral variant FTD (bvFTD), primary progressive aphasia (PPA) affecting language, and disorders primarily affecting movements, such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). The US FDA has not approved any drug to treat frontotemporal dementia.

• The annual prevalence of FTD varies from 18 to 25 cases per 100,000 individuals in the USA. FTD ranks as the second most common form of dementia among people under 65, and its prevalence is expected to increase with the aging population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: